CEO Francisco Salva outlined strategic reorientation initiatives following a $10.5M financing in March, expanding beyond precision dermatology into cosmetic ingredients and biotech tools. The company aims to leverage microbial genetic engineering technology to participate in larger markets with shorter development timelines.